March 12, 2020 / 7:51 AM / 23 days ago

BRIEF-Lysogene Completes 7.7 Million Euros Capital Increase

March 12 (Reuters) - Lysogene SA:

* COMPLETES A €7.7 MILLION CAPITAL INCREASE LED BY ORBIMED AND BY ITS SHAREHOLDER AND PARTNER SAREPTA

* SUBSCRIPTION PRICE OF 2.83 EUROS PER SHARE

* PROCEEDS WILL BE USED TO FINANCE CLINICAL PHASE 1-3 OF LYS-GM101 IN TREATMENT OF GM1 GANGLIOSIDOSIS, THE COMMERCIAL LAUNCH IN EUROPE OF LYS-SAF302, AND GENERAL CORPORATE COSTS

* AT THE END OF SETTLEMENT-DELIVERY SCHEDULED FOR MARCH 16, 2020, LYSOGENE’S SHARE CAPITAL WILL AMOUNT TO 4.9 MILLION EUROS DIVIDED INTO 16,387,510 SHARES

* NEW SHARES REPRESENT 17% OF THE NUMBER OF OUTSTANDING SHARES AFTER THE CAPITAL INCREASE Source text : bwnews.pr/2vO8R1T Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below